Creative Biolabs offers an exclusive in vivo phage display platform for clients to identify homing peptides specific for human synovium. These peptides could be used as targeting devices for delivering therapeutic/diagnostic agents to human joints. This innovative platform combines the in vivo biopanning method with a human/SCID mouse transplantation model. Our scientists are aimed to provide a reliable and specific selection system to fit very unique research objectives from our global customers.

Background

Synovium, also known as synovial membrane or stratum synovial, is soft tissue found between the joint capsule and the joint cavity of synovial joints. One common disease relates to synovium is the rheumatoid arthritis (RA). RA can be recognized by the proliferative synovitis which is involved in cartilage and bone damage and then resulting in progressive joint destruction. The present study suggests the synovial micro vascular endothelium (MVE) are mainly involved in the pathogenesis of rheumatoid arthritis (RA). During the chronic phase of RA synovitis, synovial MVE plays an important role to let inflammatory cells from the bloodstream enter to the joint. Thereby, synovial MVE seems to be an ideal therapeutic target for the development of joint-specific drug. Fortunately, the novel in vivo phage display technology is now available from Creative Biolabs to select synovial MVE-specific peptides. The drugs based on these peptides can better recognize in vivo synovial MVE and are expected to increase efficacy while decrease the possible systemic toxicity.

Human Synovium Targeting In Vivo Phage Library Screening Platform

Creative Biolabs has developed a novel platform to target human tissues and transplant into SCID mice directly for in vivo phage display selection. Through this platform, it is available to select and identify numerous homing peptides from human synovial MVE with in vivo molecular structure and functional state. In this way, a batch of synovial MVE-specific peptides with high specificity can be obtained and are possible to be developed as a specific delivery system for therapeutic or diagnostic agents. If succeed, this system may possess considerable potential for impacting the treatment of arthritic conditions.

Creative Biolabs is the only company which offers the one-stop custom services for identifying human tissue homing peptides. With years of phage display experiences in the field of organ-specific endothelium targeting, our technical scientists are confident in providing our customers with a first-class service to meet their research requirements.

Fig.1 Schematic representation of in vivo Phage Display.¹

Other optional in vivo phage display screening services:

• In Vivo Phage Display for Muscle Targeting
• In Vivo Phage Display for Atherosclerosis Targeting
• In Vivo Phage Display for Tumor Targeting
• In Vivo Phage Display for Vascular Endothelium Targeting

FAQ

1. What is human synovium-targeting in vivo phage display library screening?

   Human synovium-targeting in vivo phage display library screening is a specialized method used to discover peptides or proteins that specifically bind to synovial tissue in joints. This technique utilizes bacteriophage libraries to identify potential ligands that can localize selectively to the synovium, which is critical in diseases like arthritis.

2. Why focus on targeting the human synovium in medical research?

   Focusing on targeting the human synovium is vital for developing therapies for rheumatic diseases such as rheumatoid arthritis and osteoarthritis. Targeted therapies can potentially deliver drugs directly to the inflamed synovium, reducing systemic side effects and increasing treatment efficacy by modulating local immune responses or degrading pathological extracellular matrix components.

3. What applications does synovium-targeting phage display have?

   This technique has applications in the development of targeted drug delivery systems for anti-inflammatory therapies, regenerative medicine to promote synovial healing, and diagnostics for early detection of joint diseases. It also aids in the identification of new biomarkers for synovial inflammation and degradation.

4. What types of molecules are typically identified in synovium-targeting phage display?

   Typically, peptides that bind to specific markers of synovial cells or extracellular matrix proteins altered in disease states are identified. These can include ligands for receptors overexpressed during inflammation or peptides that bind to disease-specific molecular patterns within the joint environment.

5. How does synovium-targeting in vivo phage display differ from other tissue-targeting techniques?

   Synovium-targeting must account for the unique environment of joint spaces, characterized by varying cellular compositions and dynamic responses to mechanical stress and injury. The technique also needs to address challenges posed by the dense extracellular matrix and the typically avascular nature of cartilaginous tissues adjacent to the synovium.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.